Pesquisar
Celularity Inc
CELUAdicionar à lista de desejos
0.604USD
+0.006+1.07%
Fechamento 07/01, 16:00（ET）Cotações atrasadas em 15 min
17.43MValor de mercado
PerdaP/L TTM
Mais detalhes de Celularity Inc Empresa
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
Informações de Celularity Inc
Código da empresaCELU
Nome da EmpresaCelularity Inc
Data de listagemMay 23, 2019
CEOHariri (Robert J)
Número de funcionários123
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 23
Endereço170 Park Ave
CidadeFLORHAM PARK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal07932
Telefone19087682170
Sitehttps://celularity.com/
Código da empresaCELU
Data de listagemMay 23, 2019
CEOHariri (Robert J)
Executivos da empresa Celularity Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.86M
+0.07%
Mr. Vincent Levien
Mr. Vincent Levien
Independent Director
Independent Director
157.55K
+18.31%
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Carlos Ramirez
Mr. Carlos Ramirez
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.86M
+0.07%
Mr. Vincent Levien
Mr. Vincent Levien
Independent Director
Independent Director
157.55K
+18.31%
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Celularity Inc?
Os cinco principais acionistas de Celularity Inc são: Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Quantas instituições possuem ações da Celularity Inc (CELU)?
Em 2026Q1, 64 instituições possuíam ações da Celularity Inc, com valor de mercado aproximado de 3.75M, representando 12.95% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -258480.00.